Moguisteine is a non-narcotic, peripherally acting
antitussive.[1] In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with
COPD, compared to placebo.[2] It has also been studied in small trials in comparison to codeine[3] and dextromethorphan,[4] and has similar efficacy to both. It has not been approved for use in the United States.[5]
It was discovered by searching for
expectorants of the
thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class.[6] Its mechanism of action may be the activation of
ATP-sensitive potassium channels.[7]
^Aversa C, Cazzola M, Clini V, Dal Negro R, Maiorano V, Tana F, Allegra L (1993). "Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases". Drugs Under Experimental and Clinical Research. 19 (6): 273–9.
PMID8013271.
^Barnabè R, Berni F, Clini V, Pirrelli M, Pisani Ceretti A, Robuschi M, et al. (April 1995). "The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough". Monaldi Archives for Chest Disease = Archivio Monaldi per le Malattie del Torace. 50 (2): 93–7.
PMID7613554.
^Del Donno M, Aversa C, Corsico R, Foresi A, Grassi V, Malerba M, et al. (1994). "Efficacy and Safety of Moguisteine in Comparison with Dextromethorphan in Patients with Persistent Cough". Drug Investigation. 7 (2): 93–100.
doi:
10.1007/BF03257404.
S2CID72285850.
^Gandolfi CA, Di Domenico R, Spinelli S, Gallico L, Fiocchi L, Lotto A, et al. (February 1995). "N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate". Journal of Medicinal Chemistry. 38 (3): 508–25.
doi:
10.1021/jm00003a014.
PMID7853344.
^Morita K, Kamei J (April 2000). "Involvement of ATP-sensitive K(+) channels in the anti-tussive effect of moguisteine". European Journal of Pharmacology. 395 (2): 161–4.
doi:
10.1016/s0014-2999(00)00197-7.
PMID10794823.